Stock CGS COGSTATE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cogstate Limited

Equities

CGS

AU000000CGS8

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-26 EDT 		5-day change 1st Jan Change
1.37 AUD +3.40% Intraday chart for Cogstate Limited +5.38% -5.19%
04-01 Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment MT
02-22 Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With an expected P/E ratio at 44.82 and 35.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
COGSTATE LIMITED Stock Cogstate Limited
-5.19% 153M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
A
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CGS Stock
  4. Ratings Cogstate Limited